Hubbry Logo
Cystatin CCystatin CMain
Open search
Cystatin C
Community hub
Cystatin C
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Cystatin C
Cystatin C
Cystatin C
View on Wikipedia
from Wikipedia
CST3
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCST3, ARMD11, HEL-S-2, cystatin C
External IDsOMIM: 604312; MGI: 102519; HomoloGene: 78; GeneCards: CST3; OMA:CST3 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1471

13010

Ensembl

ENSG00000101439

ENSMUSG00000027447

UniProt

P01034

P21460

RefSeq (mRNA)

NM_001288614
NM_000099

NM_009976

RefSeq (protein)

NP_000090
NP_001275543

NP_034106

Location (UCSC)Chr 20: 23.63 – 23.64 MbChr 2: 148.71 – 148.72 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Cystatin C or cystatin 3 (formerly gamma trace, post-gamma-globulin, or neuroendocrine basic polypeptide),[5] a protein encoded by the CST3 gene, is mainly used as a biomarker of kidney function. Recently, it has been studied for its role in predicting new-onset or deteriorating cardiovascular disease. It also seems to play a role in brain disorders involving amyloid (a specific type of protein deposition), such as Alzheimer's disease. In humans, all cells with a nucleus (cell core containing the DNA) produce cystatin C as a chain of 120 amino acids. It is found in virtually all tissues and body fluids. It is a potent inhibitor of lysosomal proteinases (enzymes from a special subunit of the cell that break down proteins) and probably one of the most important extracellular inhibitors of cysteine proteases (it prevents the breakdown of proteins outside the cell by a specific type of protein degrading enzymes). Cystatin C belongs to the type 2 cystatin gene family.

Role in medicine

[edit]

Kidney function

[edit]
See also: Renal function

Glomerular filtration rate (GFR), a marker of kidney health, is most accurately measured by injecting compounds such as inulin, radioisotopes such as 51chromium-EDTA, 125I-iothalamate, 99mTc-DTPA or radiocontrast agents such as iohexol, but these techniques are complicated, costly, time-consuming and have potential side-effects.[6][7] Creatinine is the most widely used biomarker of kidney function. It is inaccurate at detecting mild renal impairment, and levels can vary with muscle mass but not with protein intake. Urea levels might change with protein intake.[8] Formulas such as the Cockcroft and Gault formula and the MDRD formula (see Renal function) try to adjust for these variables.

Cystatin C has a low molecular weight (approximately 13.3 kilodaltons), and it is removed from the bloodstream by glomerular filtration in the kidneys. If kidney function and glomerular filtration rate decline, the blood levels of cystatin C rise. Cross-sectional studies (based on a single point in time) suggest that serum levels of cystatin C are a more precise test of kidney function (as represented by the glomerular filtration rate, GFR) than serum creatinine levels.[7][9] Longitudinal studies (following cystatin C over time) are sparse, but some show promising results.[10][11][12] Although studies are somewhat divergent, most studies find that cystatin C levels are less dependent on age, gender, ethnicity, diet, and muscle mass compared to creatinine,[13][14] and that cystatin C is equal or superior to the other available biomarkers in a range of different patient populations, including diabetic patients, in chronic kidney disease (CKD), and after kidney transplant.[15] It has been suggested that cystatin C might predict the risk of developing CKD, thereby signaling a state of 'preclinical' kidney dysfunction.[16] Additionally, the age-related rise in serum cystatin C is a powerful predictor of adverse age-related health outcomes, including all-cause mortality, death from cardiovascular disease, multimorbidity, and declining physical and cognitive function.[17] The UK's National Institute for Health and Care Excellence (NICE) guideline for the assessment and management of CKD in adults concluded that using serum cystatin C to estimate GFR is more specific for important disease outcomes than use of serum creatinine, and may reduce overdiagnosis in patients with a borderline diagnosis, reducing unnecessary appointments, patient worries, and the overall burden of CKD in the population.[18]

Studies have also investigated cystatin C as a marker of kidney function in the adjustment of medication dosages.[19][20]

Cystatin C levels have been reported to be altered in patients with cancer,[21][22][23] (even subtle) thyroid dysfunction[24][25][26] and glucocorticoid therapy in some[27][28] but not all[29] situations. Other reports have found that levels are influenced by cigarette smoking and levels of C-reactive protein.[30] However, inflammation does not cause an increase in the production of cystatin C, since elective surgical procedures, producing a strong inflammatory response in patients, do not change the plasma concentration of cystatin C.[medical citation needed] Levels seem to be increased in HIV infection, which might or might not reflect actual renal dysfunction.[31][32][33] The role of cystatin C to monitor GFR during pregnancy remains controversial.[34][35] Like creatinine, the elimination of cystatin C via routes other than the kidney increases with worsening GFR.[36]

Death and cardiovascular disease

[edit]

Kidney dysfunction increases the risk of death and cardiovascular disease.[37][38] Several studies have found that increased levels of cystatin C are associated with the risk of death, several types of cardiovascular disease (including myocardial infarction, stroke, heart failure, peripheral arterial disease and metabolic syndrome) and healthy aging.[citation needed][clarification needed] Some studies have found cystatin C to be better in this regard than serum creatinine or creatinine-based GFR equations.[39][40][41][42][43][44][45][46][47][48][49][50] Because the association of cystatin C with long term outcomes has appeared stronger than what could be expected for GFR, it has been hypothesized that cystatin C might also be linked to mortality in a way independent of kidney function.[51] In keeping with its housekeeping gene properties, it has been suggested that cystatin C might be influenced by the basal metabolic rate.[52]

Proposed shrunken pore syndrome

[edit]

The glomerular sieving coefficients for 10–30 kDa plasma proteins in the human kidney are relatively high with coefficients between 0.9 and 0.07.[medical citation needed][53] These relatively high sieving coefficients, combined with the high production of ultrafiltrate in health, means that proteins less than or equal to 30 kDa in plasma normally are mainly cleared by the kidneys and at least 85% of the clearance of cystatin C occurs in the kidney.[medical citation needed][54] If the pores of the glomerular membrane shrink, the filtration of bigger molecules, e.g. cystatin C, will decrease, whereas the filtration of small molecules, like water and creatinine, will be less affected. In this case, cystatin C-based estimates of GFR, eGFRcystatin C, will be lower than creatinine-based estimates eGFRcreatinine, so that a hypothesized condition, named shrunken pore syndrome, is identified by a low eGFRcystatin C/eGFRcreatinine-ratio.[medical citation needed][55] This syndrome is associated with a very strong increase in mortality.[56]

Neurologic disorders

[edit]

Mutations in the cystatin 3 gene are responsible for the Icelandic type of hereditary cerebral amyloid angiopathy, a condition predisposing to intracerebral haemorrhage, stroke and dementia.[57][58] The condition is inherited in a dominant fashion. The monomeric cystatin C forms dimers and oligomers by domain swapping[59] and the structures of both the dimers[60] and oligomers[61] have been determined.

Since cystatin 3 also binds amyloid β and reduces its aggregation and deposition, it is a potential target in Alzheimer's disease.[62][63] Although not all studies have confirmed this, the overall evidence is in favor of a role for CST3 as a susceptibility gene for Alzheimer's disease.[64] Cystatin C levels have been reported to be higher in subjects with Alzheimer's disease.[65]

The role of cystatin C in multiple sclerosis and other demyelinating diseases (characterized by a loss of the myelin nerve sheath) remains controversial.[66]

Other roles

[edit]

Cystatin C levels are decreased in atherosclerotic (so-called 'hardening' of the arteries) and aneurysmal (saccular bulging) lesions of the aorta.[67][68][69][70] Genetic and prognostic studies also suggest a role for cystatin C.[71][72] Breakdown of parts of the vessel wall in these conditions is thought to result from an imbalance between proteinases (cysteine proteases and matrix metalloproteinases, increased) and their inhibitors (such as cystatin C, decreased).

A few studies have looked at the role of cystatin C or the CST3 gene in age-related macular degeneration.[73][74] Cystatin C has also been investigated as a prognostic marker in several forms of cancer.[75][76] Its role in pre-eclampsia remains to be confirmed.[77][78][79][80]

Laboratory measurement

[edit]

Cystatin C can be measured in a random sample of serum (the fluid in blood from which the red blood cells and clotting factors have been removed) using immunoassays such as nephelometry or particle-enhanced turbidimetry.[81] It is a more expensive test than serum creatinine (around $2 or $3, compared to $0.02 to $0.15), which can be measured with a Jaffe reaction.[82][83][84]

Reference values differ in many populations and with sex and age. Across different studies, the mean reference interval (as defined by the 5th and 95th percentile) was between 0.52 and 0.98 mg/L. For women, the average reference interval is 0.52 to 0.90 mg/L with a mean of 0.71 mg/L. For men, the average reference interval is 0.56 to 0.98 mg/L with a mean of 0.77 mg/L.[81] The normal values decrease until the first year of life, remaining relatively stable before they increase again, especially beyond age 50.[85][86][87] Creatinine levels increase until puberty and differ according to gender from then on, making their interpretation problematic for pediatric patients.[86][88]

In a large study from the United States National Health and Nutrition Examination Survey, the reference interval (as defined by the 1st and 99th percentile) was between 0.57 and 1.12 mg/L. This interval was 0.55 - 1.18 for women and 0.60 - 1.11 for men. Non-Hispanic blacks and Mexican Americans had lower normal cystatin C levels.[85] Other studies have found that in patients with an impaired renal function, women have lower and blacks have higher cystatin C levels for the same GFR.[89] For example, the cut-off values of cystatin C for CKD for a 60-year-old white women would be 1.12 mg/L and 1.27 mg/L in a black man (a 13% increase). For serum creatinine values adjusted with the MDRD equation, these values would be 0.95 mg/dL to 1.46 mg/dL (a 54% increase).[90]

Based on a threshold level of 1.09 mg/L (the 99th percentile in a population of 20- to 39-year-olds without hypertension, diabetes, microalbuminuria or macroalbuminuria or higher than stage 3 chronic kidney disease), the prevalence of increased levels of cystatin C in the United States was 9.6% in subjects of normal weight, increasing in overweight and obese individuals.[91] In Americans aged 60 and 80 and older, serum cystatin is increased in 41% and more than 50%.[85]

Molecular biology

[edit]

The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. The cystatin locus on the short arm of chromosome 20 contains the majority of the type 2 cystatin genes and pseudogenes.

The CST3 gene is located in the cystatin locus and comprises 3 exons (coding regions, as opposed to introns, non-coding regions within a gene), spanning 4.3 kilo-base pairs. It encodes the most abundant extracellular inhibitor of cysteine proteases. It is found in high concentrations in biological fluids and is expressed in virtually all organs of the body (CST3 is a housekeeping gene). The highest levels are found in semen, followed by breastmilk, tears and saliva. The hydrophobic leader sequence indicates that the protein is normally secreted. There are three polymorphisms in the promoter region of the gene, resulting in two common variants.[92] Several single nucleotide polymorphisms have been associated with altered cystatin C levels.[93]

Cystatin C is a non-glycosylated, basic protein (isoelectric point at pH 9.3). The crystal structure of cystatin C is characterized by a short alpha helix and a long alpha helix which lies across a large antiparallel, five-stranded beta sheet. Like other type 2 cystatins, it has two disulfide bonds. Around 50% of the molecules carry a hydroxylated proline. Cystatin C forms dimers (molecule pairs) by exchanging subdomains; in the paired state, each half is made up of the long alpha helix and one beta strand of one partner, and four beta strands of the other partner.[94]

History

[edit]

Cystatin C was first described as 'gamma-trace' in 1961 as a trace protein together with other ones (such as beta-trace) in the cerebrospinal fluid and in the urine of people with kidney failure.[95] Grubb and Löfberg first reported its amino acid sequence.[95] They noticed it was increased in patients with advanced kidney failure.[96] It was first proposed as a measure of glomerular filtration rate by Grubb and coworkers in 1985.[97][98]

Use of serum creatinine and cystatin C was found very effective in accurately reflecting the GFR in a study reported in the July 5, 2012, issue of the New England Journal of Medicine.[99]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Cystatin C

View on Grokipedia
from Grokipedia
Cystatin C is a low-molecular-weight (13 ) protein that functions as an endogenous inhibitor of proteases, belonging to the type II cystatin superfamily, and is widely recognized as a for (GFR) to assess function. Produced constitutively by all nucleated cells at a relatively constant rate, it is freely filtered by the glomeruli, almost completely reabsorbed and catabolized by proximal renal tubules without significant tubular secretion, which contributes to its reliability as an indicator of renal clearance independent of factors like age, sex, muscle mass, or diet. Encoded by the CST3 gene on , cystatin C plays key roles in regulating and has been implicated in pathological processes such as amyloid deposition in hereditary . Structurally, the mature form of human cystatin C is a single-chain polypeptide comprising 120 amino acids, stabilized by two conserved disulfide bonds (between Cys73–Cys83 and Cys97–Cys117), which confer resistance to degradation and enable tight binding to target proteases via a conserved glycine residue at position 11. It primarily inhibits lysosomal cysteine proteases, including cathepsins B, H, L, and S, thereby modulating processes like antigen presentation, bone resorption, and phagocytosis in immune cells. Beyond renal applications, elevated cystatin C levels have been associated with cardiovascular risk, neuroprotection, and tumorigenesis, highlighting its multifaceted biological significance. In clinical practice, serum cystatin C is a superior alternative to for estimating GFR, particularly in early-stage (CKD) where it detects subtle declines (e.g., GFR 60–90 mL/min/1.73 m²) with higher sensitivity, as evidenced by meta-analyses showing improved (ROC) curves. The 2024 KDIGO guidelines recommend estimating GFR using both and cystatin C for greater accuracy than either alone. It is especially valuable in vulnerable populations, such as pediatric patients, the elderly, those with , or post-renal transplant recipients, where creatinine-based estimates may be confounded. However, its use is tempered by higher costs, potential interferences from corticosteroids or dysfunction, and the need for standardized measurement methods.

Structure and biochemistry

Protein structure

Cystatin C is a non-glycosylated protein composed of 120 residues, exhibiting a molecular weight of approximately 13.3 . It belongs to the type 2 subfamily of the cystatin superfamily, which is defined by a conserved cystatin fold comprising a twisted antiparallel five-stranded β-sheet that envelops a central α-helix. This compact structure, approximately 3.4 nm in diameter, confers high stability to the protein under physiological conditions. The overall fold is stabilized by two intramolecular disulfide bonds located in the C-terminal region: one linking cysteine residues 73 and 83, and the other connecting residues 97 and 117. These bonds help maintain the integrity of the β-sheet and α-helix core, preventing unfolding and contributing to the protein's resistance to . Key structural motifs critical for function include the N-terminal loop (residues 9–15), which forms part of the substrate-mimicking inhibitory wedge, and the conserved at position 105 and at 106 within the second β-hairpin loop, which participate in electrostatic and hydrophobic interactions during binding. The first loop motif, centered around the conserved QIVAG sequence (residues 53–57), further supports the inhibitory architecture by providing hydrophobic contacts. The three-dimensional structure of human cystatin C has been elucidated through , with representative monomeric models (e.g., PDB ID: 3GAX) confirming its existence as a in solution, despite a propensity for domain swapping and dimerization under certain conditions. Unlike some family members, cystatin C undergoes no significant post-translational modifications in its standard form, enhancing its chemical homogeneity, thermal stability, and unimpeded glomerular filtration. This lack of or other alterations ensures consistent physicochemical properties across biological fluids.

Gene and synthesis

Cystatin C is encoded by the , located on the short arm of human at position 20p11.21. The gene spans approximately 12 kilobases of genomic DNA and consists of three exons, with the coding sequence distributed across these exons to produce transcript variants that encode the cystatin C precursor protein. The promoter region of CST3 lacks typical TATA or CAAT boxes but contains multiple binding sites for the , which plays a key role in driving its constitutive expression. This GC-rich promoter architecture supports the gene's function, enabling steady transcription across diverse cell types without reliance on inducible elements. CST3 is ubiquitously expressed in all nucleated cells at relatively constant rates, reflecting its as a fundamental inhibitor, with mRNA levels remaining stable under normal physiological conditions. The protein is synthesized on ribosomes as a 146-amino-acid preprotein, featuring an N-terminal 26-amino-acid that directs it to the secretory pathway and is subsequently cleaved in the to produce the mature, secreted form. In healthy adults, the production rate is estimated at approximately 2 mg/kg/day, contributing to its utility as a stable . Certain mutations in CST3 are linked to hereditary , a condition characterized by deposition in cerebral blood vessels. The Icelandic-type variant, known as B-Leu68Gln (resulting from a c.281T>A substitution in the coding sequence), destabilizes the , promoting dimer formation and fibril aggregation, which leads to brain hemorrhage and typically in mid-adulthood. This mutation is highly penetrant in homozygous individuals and has been mapped to the gene's second .

Biological functions

Cysteine protease inhibition

Cystatin C functions as a potent endogenous inhibitor of papain-like proteases, including cathepsins B, H, L, and S, by targeting the cysteine residue essential for their catalytic activity. This inhibition occurs through conserved structural motifs, such as the N-terminal Gly-Gly sequence and the QVVAG and PW loops, which insert into the protease's active site cleft to block substrate access. The binding mechanism involves a reversible, driven by electrostatic and hydrophobic forces, forming a tight complex with dissociation constants in the nanomolar range; for example, the equilibrium (K_d) for the cystatin C- complex is approximately 0.3 nM. This process follows a two-step model: an initial weak association (K_1 ≈ 50-70 μM) via the N-terminal region of cystatin C with the protease's S2 and S3 subsites, followed by a conformational change (k_{+2} ≈ 150 s^{-1}) that displaces the occluding loop in , locking the inhibitor in place. Inhibition kinetics adhere to the competitive model, where cystatin C competes with the substrate for the active site, as described by the modified Michaelis-Menten equation: v=Vmax⁡[S]Km(1+[I]Ki)+[S]v = \frac{V_{\max} [S]}{K_m \left(1 + \frac{[I]}{K_i}\right) + [S]} Here, vv is the initial velocity, Vmax⁡V_{\max} the maximum velocity, [S][S] the substrate concentration, KmK_m the Michaelis constant, [I][I] the inhibitor concentration, and KiK_i the inhibition constant, reflecting cystatin C's high-affinity binding. By regulating activity, cystatin C prevents excessive in key physiological processes, including lysosomal protein degradation, remodeling, and in immune cells. This modulation maintains cellular by balancing degradative events without completely abolishing function. Alterations in cystatin C levels influence these regulatory roles; elevated expression suppresses -driven degradation, thereby protecting against potential tissue damage during inflammatory responses, while deficiencies result in unchecked activity that may exacerbate degradative processes in degenerative contexts.

Tissue distribution and regulation

Cystatin C is a low-molecular-weight protein produced at a constant rate by virtually all nucleated cells throughout the body. Its gene (CST3) exhibits widespread expression across human tissues, with relatively higher mRNA levels in the , , , and reproductive organs such as the , alongside notable presence in other organs such as the intestine and . In healthy adults, serum cystatin C concentrations typically range from 0.6 to 1.0 mg/L, reflecting a balance between steady production and primarily renal clearance. These levels remain relatively stable and independent of factors such as age, , and muscle mass, distinguishing cystatin C from other markers like . Regarding renal handling, cystatin C is freely filtered at the due to its small (approximately 13 ) and lack of protein binding. Nearly all filtered cystatin C is subsequently reabsorbed and completely degraded by proximal tubular epithelial cells, with minimal urinary excretion under normal conditions; thus, serum concentrations primarily represent the difference between systemic production and . Non-renal elimination appears limited, though minor may occur in tissues such as and leukocytes, particularly in conditions involving high cellular turnover like , where elevated levels suggest additional extrarenal influences on clearance or production. Regulation of cystatin C expression and serum levels is influenced by several physiological factors. Inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), are associated with elevated serum cystatin C levels, as evidenced by correlations between serum levels and markers of . Glucocorticoids also upregulate cystatin C synthesis, leading to elevated serum concentrations independent of changes in ; for instance, administration has been shown to promote hepatic production of the protein. Thyroid function exerts a notable modulatory effect, with serum cystatin C levels typically 20-30% higher in and lower in compared to euthyroid states, likely due to alterations in production rate rather than clearance. Additionally, cystatin C demonstrates circadian stability, with only minor daily fluctuations (typically <10%), in contrast to creatinine, which exhibits greater variability influenced by dietary and activity factors.

Measurement and assays

Laboratory techniques

Cystatin C is primarily quantified in biological samples using automated immunoassays that detect antigen-antibody complexes through light scattering. The particle-enhanced turbidimetric immunoassay (PETIA) is a widely adopted method, where cystatin C binds to polyclonal antibodies coated on latex particles, forming aggregates that increase solution turbidity measured by absorbance at 334 nm or similar wavelengths. This technique is implemented on high-throughput platforms such as the Roche Tina-quant system, enabling rapid processing of serum and plasma samples with high precision. Nephelometric assays provide an alternative approach, quantifying the intensity of light scattered at a 70-degree angle by immune complexes formed with monoclonal or polyclonal antibodies. These are commonly performed on analyzers like the Siemens BN II system, which supports both serum and plasma and offers a broad dynamic range from 0.06 to 9.4 mg/L. Both PETIA and nephelometry demonstrate low imprecision, with total coefficients of variation typically under 5% across clinical ranges, facilitating reliable inter-laboratory comparisons. Assay calibration is traceable to the certified reference material ERM-DA471/IFCC, a human serum standard with a certified cystatin C concentration of 5.48 mg/L, developed by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) in collaboration with the World Health Organization and released in 2010. This standardization has significantly reduced inter-assay variability to less than 5% and minimized biases between methods, such as those observed in pre-2010 calibrations. For IFCC-traceable assays, the reference range in healthy adults is approximately 0.62–1.11 mg/L in serum, though values may vary slightly by platform and population demographics. Sample collection requires serum or plasma, with separation from cells recommended within 2 hours to avoid hemolysis; specimens remain stable for up to 7 days when refrigerated at 2–8°C and longer when frozen at -20°C or below. Urine cystatin C levels are low in healthy individuals (typically 0.06–0.16 mg/L), reflecting near-complete reabsorption by proximal tubules, but rise substantially in cases of tubular damage, serving as an indicator of renal injury. Recent advances include point-of-care devices and microfluidic platforms for faster detection outside traditional labs. Electrochemical biosensors, often incorporating gold nanoparticles or silicon nanowires for signal amplification, achieve limits of detection as low as 0.1 ng/mL, enabling rapid, portable assessment in settings like emergency departments. These innovations leverage biorecognition elements such as antibodies or aptamers integrated with nanomaterials to enhance sensitivity and reduce assay time to minutes.

Comparison to other biomarkers

Cystatin C offers several advantages over creatinine as a biomarker for estimating glomerular filtration rate (GFR), particularly in assessing renal function. Unlike creatinine, which is heavily influenced by muscle mass, diet, age, and sex, cystatin C production remains relatively constant across individuals, resulting in fewer non-GFR determinants and providing a more stable reflection of kidney filtration. This stability allows cystatin C to detect mild chronic kidney disease (CKD) at GFR levels of 60-90 mL/min/1.73 m² earlier than creatinine-based estimates, where subtle declines may be masked by extrarenal factors. Additionally, cystatin C exhibits lower variability from inflammatory conditions compared to creatinine, with studies indicating reduced bias in diverse populations due to its independence from muscle-related influences. Despite these benefits, cystatin C has notable limitations relative to creatinine. Its measurement is more expensive, typically costing 2-3 times as much per test (approximately $5-10 versus $2-3 for creatinine), which can limit routine clinical adoption. Cystatin C levels can also be affected by non-renal factors, including thyroid dysfunction (elevated in hyperthyroidism), corticosteroid use, and smoking, potentially leading to overestimation of GFR in these scenarios. In dialysis patients, cystatin C levels reflect both residual renal function and dialyzer clearance, making it a useful marker for assessing dialysis adequacy and residual kidney function, though interpretation requires consideration of these factors. The combined use of cystatin C and creatinine in estimating equations, such as the CKD-EPI formulation, enhances overall accuracy. Equations incorporating both markers achieve a P30 accuracy (GFR estimates within 30% of measured values) of over 90%, compared to approximately 85-87% for creatinine alone, improving reliability across a broader range of kidney function levels. Cystatin C demonstrates superior specificity in certain populations where creatinine is less reliable, such as pediatrics, the elderly, and individuals with sarcopenia. In pediatric cohorts, cystatin C-based equations more accurately estimate GFR compared to creatinine, avoiding biases from variable growth and muscle development. Meta-analyses have shown that incorporating cystatin C leads to 15-20% reclassification of CKD stages in these groups, better identifying at-risk individuals and refining prognostic assessments. Standardization efforts have further strengthened cystatin C's utility as a biomarker. Since 2011, harmonization by the National Kidney Foundation (NKF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has aligned assays to a reference material, reducing inter-assay bias to less than 10% and minimizing variability in GFR estimates across laboratories.

Medical applications

Glomerular filtration rate assessment

Cystatin C serves as a reliable biomarker for estimating glomerular filtration rate (GFR) because it is produced at a constant rate by all nucleated cells, freely filtered by the glomeruli, and reabsorbed and catabolized by proximal tubules without tubular secretion, making it less influenced by age, sex, muscle mass, or diet compared to serum creatinine. This independence enhances its utility in diverse populations for assessing kidney function. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) developed equations in 2012 to estimate GFR using cystatin C, either alone or combined with creatinine, calibrated against measured GFR using iohexol clearance in over 5,000 participants. The standalone cystatin C equation is: eGFRcys=133×min⁡(SCysC0.8,1)−0.499×max⁡(SCysC0.8,1)−1.328×0.996Age×0.932 (if female)\text{eGFR}_{\text{cys}} = 133 \times \min\left(\frac{\text{SCysC}}{0.8}, 1\right)^{-0.499} \times \max\left(\frac{\text{SCysC}}{0.8}, 1\right)^{-1.328} \times 0.996^{\text{Age}} \times 0.932 \ (\text{if female}) where SCysC is standardized serum cystatin C concentration in mg/L, age is in years, and eGFR is expressed in mL/min/1.73 m². The combined creatinine-cystatin C equation further refines accuracy by integrating both markers: eGFRcr-cys=130×(SCrκ)α×(SCysC0.8)−0.499×0.996Age×0.932 (if female)\text{eGFR}_{\text{cr-cys}} = 130 \times \left(\frac{\text{SCr}}{\kappa}\right)^{\alpha} \times \left(\frac{\text{SCysC}}{0.8}\right)^{-0.499} \times 0.996^{\text{Age}} \times 0.932 \ (\text{if female}) with κ = 0.7 for females and 0.9 for males, α = −0.248 for females if SCr ≤ 0.7 mg/dL or −0.207 if >0.7 mg/dL (similarly adjusted for males), and SCr as in mg/dL. These equations outperform creatinine-only estimates, achieving higher accuracy (P30 of 85.9% for the combined equation vs. 80.4% for creatinine alone) and better precision across GFR ranges. Cystatin C-based eGFR demonstrates superior diagnostic performance for identifying reduced GFR, particularly below 60 mL/min/1.73 m², with area under the curve (AUC) values of approximately 0.92 compared to 0.85 for creatinine-based estimates in validation cohorts. The : Improving Global Outcomes (KDIGO) 2024 guidelines recommend cystatin C-based or combined eGFR for confirming in adults with creatinine-based eGFR of 45–59 mL/min/1.73 m² without or other markers of kidney damage, as it reduces misclassification by about 16–20% in borderline cases. In clinical practice, cystatin C is valuable for screening , where subtle GFR declines may be overlooked by creatinine due to compensatory hyperfiltration. It also aids in monitoring GFR for precise drug dosing, such as adjusting agents like , where accurate renal clearance prevents toxicity in patients with altered . In acute settings, cystatin C excels at detecting early GFR changes of 10–20%, with serum levels rising within 2–4 hours of insult, enabling earlier intervention than , which lags by 24–48 hours. However, in (AKI), cystatin C kinetics still lag behind gold-standard measured GFR methods like clearance due to distribution and equilibration delays, potentially underestimating the rapidity of GFR recovery. For pediatric patients, a cystatin C-adapted Schwartz equation—eGFR = 70.69 × (SCysC)−0.931—offers greater precision for GFR values of 30–120 mL/min/1.73 m² compared to creatinine-based formulas, as validated in the Chronic in Children (CKiD) cohort, reducing bias in children with variable growth and nutrition.

Cardiovascular disease prediction

Cystatin C serves as an independent predictor of cardiovascular events and mortality, providing prognostic information beyond traditional risk factors such as age, , and levels. In the Risk in Communities (ARIC) study, higher cystatin C concentrations were associated with strengthened predictions of incident and all-cause mortality when incorporated into estimated calculations, highlighting its value in community-based cohorts. A 2019 meta-analysis of patients with further demonstrated that elevated cystatin C levels confer a 2.27-fold increased of all-cause mortality (95% CI: 1.81-2.84), independent of creatinine-based measures. Similarly, prospective analyses have reported hazard ratios of 1.22 to 1.44 per standard deviation increase in cystatin C for incident and mortality, with effects persisting after adjustment for renal function. The prognostic utility of cystatin C in stems from its reflection of underlying pathophysiological processes, including low-grade and heightened vascular activity. As an inhibitor of cysteine proteases like cathepsins, cystatin C modulates remodeling; imbalances favor cathepsin-mediated degradation, promoting plaque instability and progression. Epidemiological evidence links higher circulating cystatin C to inflammatory states in vascular tissues, where it may serve as a compensatory response to protease-driven , independent of . This dual role—as both a renal marker and a modulator of inflammatory and proteolytic pathways—underpins its association with adverse cardiovascular outcomes, such as and . In risk stratification, cystatin C levels exceeding 1.0 mg/L are associated with substantially elevated cardiovascular mortality in general populations and high-risk groups. For instance, in patients with peripheral arterial disease, cystatin C >1.0 mg/L predicted a 3.2-fold adjusted for cardiovascular death (95% CI: 1.39-7.59), even among those without overt renal impairment. This threshold enhances identification of at-risk individuals, and cystatin C has been integrated into modified risk assessment tools, such as variants of the , to refine predictions of coronary heart disease and over 10 years. Such applications improve reclassification of intermediate-risk patients, offering a more nuanced evaluation than alone. Clinical evidence from large-scale analyses supports cystatin C's additive prognostic value in heart failure management, particularly when combined with established biomarkers like and B-type natriuretic peptide (BNP). A 2019 meta-analysis encompassing over 5,000 heart failure patients confirmed that cystatin C independently predicts rehospitalization and mortality, augmenting models that include and BNP for better outcome forecasting. Recent prospective cohort studies, including those from 2023, have shown that integrating cystatin C with NT-proBNP enhances cardiovascular in broader populations, with combined models improving net reclassification by up to 15% in elderly individuals through better discrimination of high-risk subgroups. These findings underscore cystatin C's role in personalized , especially in older adults where renal and cardiac comorbidities overlap.

Shrunken pore syndrome

Shrunken pore syndrome (SPS) is a renal disorder defined by a selective impairment in the glomerular filtration of proteins and peptides with molecular masses between 5 and 30 kDa, while filtration of smaller molecules like (0.113 kDa) remains relatively intact. This condition is identified when the cystatin C-based estimated (eGFR_cys) is at least 30% lower than the -based eGFR (eGFR_cre), typically using the ratio eGFR_cys/eGFR_cre < 0.70 via CKD-EPI equations, excluding non-renal factors influencing cystatin C concentrations such as or use. The hallmark discrepancy arises from reduced pore size in the , limiting passage of larger solutes like cystatin C (13.3 kDa). The syndrome was proposed in 2014 by Grubb and colleagues, drawing from observations of mismatched GFR estimates in diverse clinical settings, including pregnant women and patients. Subsequent evidence confirms SPS as an independent predictor of adverse outcomes, with multiple studies reporting 2- to 3-fold increases in all-cause mortality regardless of measured GFR. For instance, a 2025 population-based of middle-aged adults found SPS associated with a 60% higher mortality (HR 1.6, 95% CI 1.3–2.0) over 25 years, while a contemporaneous study in patients with normal renal function reported a 2.55-fold elevated (HR 2.55, 95% CI 1.34–4.84). These associations hold after adjustments for confounders like age, , and comorbidities, highlighting SPS as a distinct beyond traditional CKD staging. Pathophysiologically, SPS correlates with systemic conditions including chronic inflammation, , and , which may contribute to glomerular remodeling. The retention of 10–30 kDa proteins, such as signaling molecules and protease regulators, promotes and vascular damage, potentially exacerbating tubulointerstitial through dysregulated activity—given cystatin C's role as an inhibitor of such enzymes. Proteomic analyses in SPS patients reveal elevated levels of atherosclerosis-linked proteins, supporting a mechanism of accumulated bioactive peptides driving morbidity. Prevalence in (CKD) cohorts varies but typically ranges from 5% to 10%, with higher rates (up to 23%) in advanced stages or high-risk groups like those post-; relies on CKD-EPI discordance thresholds to ensure specificity. Clinically, SPS detection warrants evaluation for vascular , as it signals heightened cardiovascular risk beyond standard GFR assessment. The KDIGO guidelines endorse cystatin C measurement to confirm eGFR in discordant cases. Such measurements can help identify conditions like SPS.

Neurological disorders

Cystatin C is implicated in hereditary (HCCAA), a rare autosomal dominant disorder caused by mutations in the CST3 gene encoding cystatin C. The most common mutation, L68Q ( to at position 68), leads to the production of a mutant protein prone to misfolding, dimerization, and deposition as in the walls of small- to medium-sized and arterioles. This results in progressive , recurrent lobar intracerebral hemorrhages, and cerebral infarcts, often manifesting in young adulthood with high lethality. Affected individuals, predominantly of Icelandic descent, experience accelerated disease progression compared to sporadic forms, underscoring cystatin C's direct pathogenic role in vascular . In , cystatin C levels exhibit dysregulation, with elevated serum concentrations observed in patients relative to healthy controls, potentially reflecting or impaired clearance. Conversely, (CSF) levels are typically reduced, suggesting altered transport across the blood-brain barrier (BBB) and possible dysfunction in its integrity. A 2020 meta-analysis of studies on —a key precursor to Alzheimer's—demonstrated that higher cystatin C levels are strongly associated with increased risk (standardized mean difference of 2.39), highlighting its prognostic value for cognitive decline. Cystatin C serves as a prognostic indicator in , where it correlates with infarct characteristics and recovery trajectories. Higher serum levels following acute ischemia are associated with better cognitive outcomes at , potentially due to enhanced inhibition of proteases like cathepsins, mitigating and neuronal damage. Initial investigations have explored its association with infarct volume and hemorrhagic transformation, though further validation is needed to establish predictive thresholds. Beyond these, cystatin C shows promise as a biomarker for relapses, with decreased CSF concentrations observed during active disease phases, potentially signaling protease dysregulation and demyelination. Studies have observed decreased CSF cystatin C concentrations in patients compared to controls. In animal models of and injury, such as experimental autoimmune (a model for ), cystatin C exerts neuroprotective effects by inhibiting cathepsin S, thereby attenuating microglial activation, inflammation, and axonal loss.

Emerging clinical uses

Cystatin C has shown promise as an early for (AKI), particularly in urinary form, where levels rise within hours following renal insult, enabling detection before changes in serum creatinine become apparent. In patients undergoing , urinary cystatin C concentrations increase significantly in those developing AKI, offering superior predictive performance compared to plasma markers like NGAL and alpha-1-microglobulin, with area under the curve (AUC) values indicating strong diagnostic utility for early tubular damage. This rapid elevation supports its role in high-risk settings such as post-surgical care, where timely intervention can mitigate progression to severe AKI stages. In kidney transplantation, cystatin C facilitates earlier detection of graft rejection compared to creatinine, as serum levels rise promptly in response to acute changes in glomerular filtration rate (GFR). Studies demonstrate that cystatin C elevations occur as early as day 3 post-transplant in rejection cases, correlating more closely with measured GFR and improving risk stratification for graft dysfunction. Recent analyses indicate that incorporating cystatin C into GFR estimation enhances prognostic accuracy for long-term outcomes, including reduced incidence of delayed graft function. Among special populations, cystatin C offers advantages in monitoring antiretroviral therapy (ART)-associated in people living with , where it provides a more stable GFR estimate than , unaffected by muscle mass variations or tenofovir-related fluctuations. A 2024 systematic highlights its high specificity and positive likelihood ratio for detecting in this cohort, potentially identifying subclinical impairment missed by creatinine-based methods. In , cystatin C avoids the overestimation of GFR seen with creatinine in neonates due to maternal creatinine transfer, allowing accurate assessment from birth onward and supporting precise dosing in vulnerable infants. For oncology patients, cystatin C-based GFR improves chemotherapy dosing accuracy, particularly in those with or , where underestimates renal function, thereby reducing risks of toxicity or undertreatment. Beyond these, cystatin C serves as an marker in , with elevated serum levels correlating with disease severity and predicting AKI onset independently of , though influenced by systemic inflammatory responses. Emerging point-of-care technologies, including electrochemical and optical biosensors, enable rapid cystatin C detection in 2025, with limits of detection as low as 0.03 ng/mL and assay times under 15 minutes, facilitating bedside GFR monitoring in resource-limited settings. Despite these advances, limitations persist, including the need for further validation in non-Caucasian populations where equation performance may vary due to genetic and environmental factors, and higher costs—approximately $18 per test versus $5–10 for creatinine—posing barriers in low-resource settings.

History and development

Discovery and initial characterization

Cystatin C, first described as gamma-trace in 1961 by Jorgen Clausen as a trace protein in cerebrospinal fluid, was identified in the 1980s as a low-molecular-weight protein exhibiting inhibitory activity against papain, a cysteine protease. Initially termed gamma-trace or post-gamma globulin due to its electrophoretic migration in the gamma region, the protein was recognized for its basic properties and abundance in biological fluids. This characterization built on earlier observations of gamma-trace in cerebrospinal fluid but emphasized its protease inhibitory function during biochemical studies in the early 1980s. In 1982, the complete of gamma-trace was determined, revealing a 120-residue polypeptide that aligned closely with known inhibitors. By 1984, further analysis confirmed its potent inhibition of and proposed the name cystatin C, positioning it as the third member of the cystatin family alongside previously identified forms such as those from chicken and rat liver. This sequencing and functional assignment highlighted cystatin C's structural similarities to chicken cystatin, an protein first characterized as a tight-binding inhibitor in the late 1970s, establishing a conserved inhibitory mechanism across species. The human form of cystatin C was isolated from the urine of patients with , where elevated levels reflected its and dynamics in the . Early studies in the late 1980s demonstrated its presence across various tissues, suggesting a broad regulatory role in activity. The CST3 cDNA was cloned in 1987, confirming its ubiquitous expression as a constitutive inhibitor produced by all nucleated cells, with the detailed in 1990.

Evolution as a clinical biomarker

In the , cystatin C emerged as a promising for (GFR) assessment, with early studies demonstrating its superiority over due to its production at a constant rate independent of age, sex, muscle mass, and diet. A pivotal 1994 study introduced a particle-enhanced turbidimetric for serum cystatin C and showed it correlated more closely with measured GFR in patients with various conditions compared to creatinine, highlighting its potential as a more sensitive marker for early renal impairment. This period also marked the development of the first commercial assays, such as the 1995 Dade Behring particle-enhanced immunoturbidimetric method, which enabled broader research and initial clinical evaluation. The 2000s saw validation of cystatin C through large-scale cohort studies, solidifying its role in (CKD) staging and risk prediction. A landmark 2013 New England Journal of Medicine study analyzed data from multiple cohorts and found that using cystatin C improved risk reclassification by 16% for death and end-stage renal disease in individuals with CKD, enhancing prognostic accuracy for cardiovascular events and mortality beyond alone. In 2010, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) established a reference material and calibration standard for cystatin C assays, addressing inter-laboratory variability and paving the way for standardized clinical use. Meta-analyses during this era confirmed that cystatin C improved GFR estimation accuracy by 10-15% in diverse populations, particularly in and the elderly. By 2012, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines endorsed cystatin C for confirming reduced eGFR (45-59 mL/min/1.73 m²) when based solely on creatinine, marking its integration into routine nephrology practice and spurring investigations into its associations with cardiovascular and neurological outcomes. In recent years, a 2022 Kidney360 review emphasized cystatin C's advantages in accuracy across populations but highlighted limitations such as thyroid influences and assay costs, urging cautious interpretation. As of 2025, updates have focused on discordance syndromes like shrunken pore syndrome—where cystatin C indicates worse GFR than creatinine—and expanded inpatient applications for acute kidney injury monitoring, supported by ongoing refinements in combined creatinine-cystatin C equations.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC2533150/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC7130541/
  3. https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC7657956/
  5. https://www.uniprot.org/uniprotkb/P01034/entry
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC10670837/
  7. https://febs.onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2010.07596.x
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC10895963/
  9. https://pubmed.ncbi.nlm.nih.gov/7890620/
  10. https://www.rcsb.org/structure/3GAX
  11. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/cystatin-c
  12. https://www.ncbi.nlm.nih.gov/gene/1471
  13. https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core%3Bg=ENSG00000101439
  14. https://www.ncbi.nlm.nih.gov/clinvar/RCV000005988
  15. https://omim.org/entry/105150
  16. https://jcancer.org/v04p0045.htm
  17. https://febs.onlinelibrary.wiley.com/doi/10.1016/S0014-5793(97)01604-9
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC7165929/
  19. https://www.jci.org/articles/view/7709
  20. https://www.mdpi.com/2073-4409/10/8/2071
  21. https://www.proteinatlas.org/ENSG00000101439-CST3/tissue
  22. https://pubmed.ncbi.nlm.nih.gov/2363674/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC6423796/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4160581/
  25. https://www.ccjm.org/content/92/9/546
  26. https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.109.856393
  27. https://pubmed.ncbi.nlm.nih.gov/16337174/
  28. https://journals.sagepub.com/doi/10.1177/0961203311425527
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC6711078/
  30. https://pubmed.ncbi.nlm.nih.gov/12675875/
  31. https://diagnostics.roche.com/global/en/products/lab/cysc2-cps-000094.html
  32. https://pubmed.ncbi.nlm.nih.gov/20446879/
  33. https://www.siemens-healthineers.com/en-us/plasma-protein/assays/n-latex-cystatin-c-assay
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC7249730/
  35. https://publications.jrc.ec.europa.eu/repository/bitstream/JRC58953/103-2010_as%2520publilshed.pdf
  36. https://www.ovid.com/journals/cclm/fulltext/10.1515/cclm.2010.318~first-certified-reference-material-for-cystatin-c-in-human
  37. https://apps.sbgh.mb.ca/labmanual/test/view?seedId=36328
  38. https://www.marshfieldlabs.org/sites/ltrm/Human/Pages/23230.aspx
  39. https://www.scirp.org/journal/paperinformation?paperid=114466
  40. https://www.tandfonline.com/doi/full/10.1080/0886022X.2020.1757463
  41. https://pubs.rsc.org/en/content/articlehtml/2025/ra/d4ra07197b
  42. https://www.sciencedirect.com/science/article/abs/pii/S0009898125005625
  43. https://www.mdpi.com/2079-6374/13/6/645
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC9717651/
  45. https://journals.lww.com/kidney360/fulltext/2022/10000/advantages%2C_limitations%2C_and_clinical.24.aspx
  46. https://www.mdpi.com/2226-4787/8/1/35
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC4446917/
  48. https://academic.oup.com/ndt/article/21/7/1855/1821840
  49. https://pubmed.ncbi.nlm.nih.gov/25274955/
  50. https://www.niddk.nih.gov/research-funding/research-programs/kidney-clinical-research-epidemiology/laboratory/glomerular-filtration-rate-equations/adults
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC11147893/
  52. https://www.nejm.org/doi/full/10.1056/NEJMoa1214234
  53. https://www.acpjournals.org/doi/10.7326/0003-4819-156-11-201203200-00391
  54. https://www.sciencedirect.com/science/article/abs/pii/S0009898116300870
  55. https://www.nejm.org/doi/full/10.1056/NEJMoa1114248
  56. https://pubmed.ncbi.nlm.nih.gov/20132068/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC8809099/
  58. https://pubmed.ncbi.nlm.nih.gov/22732340/
  59. https://journals.lww.com/cjasn/fulltext/2025/04000/the_kinetics_of_cystatin_c_and_serum_creatinine_in.5.aspx
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC3433576/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC11560791/
  62. https://portlandpress.com/bioscirep/article/39/2/BSR20181761/110932/Cystatin-C-for-predicting-all-cause-mortality-and
  63. https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.12169
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC5451109/
  65. https://www.imrpress.com/journal/FBL/13/15/10.2741/3115
  66. https://www.jacc.org/doi/10.1016/j.jacc.2016.06.037
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC3110633/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC3218629/
  69. https://www.ahajournals.org/doi/10.1161/circ.122.suppl_21.A8982
  70. https://bmjopen.bmj.com/content/13/1/e063896
  71. https://onlinelibrary.wiley.com/doi/full/10.1093/eurjhf/hfp024
  72. https://doi.org/10.1016/j.clinbiochem.2020.06.002
  73. https://doi.org/10.3389/fepid.2025.1661167
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC6308389/
  75. https://pubmed.ncbi.nlm.nih.gov/32459111/
  76. https://www.omim.org/entry/105150
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC8095917/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC8832092/
  79. https://pubmed.ncbi.nlm.nih.gov/33075778/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC6990774/
  81. https://pubmed.ncbi.nlm.nih.gov/22349874/
  82. https://onlinelibrary.wiley.com/doi/10.1002/ana.20955
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC3257513/
  84. https://pubmed.ncbi.nlm.nih.gov/22663994/
  85. https://www.researchgate.net/publication/369277474_Serum_Cystatin_C_as_a_Predictor_of_Acute_Kidney_Transplant_Rejection
  86. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1295217/full
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC11352255/
  88. https://www.nature.com/articles/s41416-025-03190-3
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC4200299/
  90. https://www.nejm.org/doi/full/10.1056/NEJMoa2203769
  91. https://pubmed.ncbi.nlm.nih.gov/6203523/
  92. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2796.2010.02238.x
  93. https://pubmed.ncbi.nlm.nih.gov/6712597/
  94. https://www.sciencedirect.com/science/article/abs/pii/S0009912004002838
Add your contribution
Related Hubs
User Avatar
No comments yet.